Nanoscience Discussion Group - Thursday, 4/21 @ 4:00 p.m.

Department of Chemistry
NY Nanoscience Discussion Group

Speakers, not necessarily in this order:


Shawn Yin
Bristol-Meyers Squibb Co.,
Drug Product Science & Technology

"Enhancing API Bioavailability via Nanotechnology for Drug Delivery"

The last few years have seen great advances in the understanding and utilizing of pharmaceutical nano-materials for poorly watersoluble compounds. Materials with features on the scale of nanometers often have properties different from their macro/meso/microscale counterparts. When applied in life science fields, nanotechnology can offer the advantages such as improving performance and quality of pharmaceutical products. This presentation will describe some basic concepts of nano-materials, the common technologies to prepare and characterize them. The advantages of using nano-sized crystalline drugs for drug delivery applications will also be demonstrated in this talk by a few examples.

Dennis Leung
Merck & Co., Inc.
Pharmaceutical Research & Development

"Nanotechnology and Pharmaceuticals: Aspects of Nanotechnology Used for Drug Delivery"

Nanotechnology has emerged as a powerful new platform for the pharmaceutical industry to help develop new drug therapies and has had a significant impact on drug development from preclinical toxicology studies to commercial marketed products. Drug nanoparticles have unique properties that can provide advantages for both general and selective drug delivery. Formulations of drug nanoparticles have emerged as a promising new dosage form for the general systemic delivery of water-insoluble drugs. Drug nanoparticles also have unique properties that allow for the selective targeting of specific tissues, resulting in higher efficacies and lower risk of side effects. An overview of current nanotechnology approaches and case studies will be presented.

Michael D. Ward
New York University
Department of Chemistry

"Inhibition of Crystal Growth at the Nanoscale: A Pathway to the Prevention of L-Cystine Kidney Stones"

Crystallization of L-cystine is a critical step in the pathogenesis of cystine kidney stones. Treatments for this disease are somewhat effective but often lead to adverse side effects. Real-time in situ atomic force microscopy (AFM) reveals that L-cystine dimethylester (L-CDME) and L-cystine methylester (L-CME) dramatically reduce the growth velocity of the six symmetry-equivalent {100} steps due to specific binding at the crystal surface, which frustrates the attachment of L-cystine molecules. The AFM observations are mirrored by reduced crystal yield and crystal size in the presence of L-CDME and L-CME, and the crystal morphology provides clues about the inhibition mechanism at the nanoscale. Moreover, these results, in combination with recent mouse model studies, suggest a new pathway to the prevention of L-cystine stones through rational design.


1003 Silver Center
Thursday, April 21, 2011
Science: 4:00 p.m. - 5:30 p.m.
Refreshments: 5:30 p.m. - 6:00 p.m.

*Sessions feature three 30-minute presentations on nanoscience, one each with strong orientation in biology, chemistry, and physics/applied mathematics.  Presentations will be focused on discussion of recent work, although speakers will be expected to place the work in a context understandable to a broad audience.

*Joint Meeting with Nanoscience Topical Group New York Section, American Chemical Society

*For more information:

Updated on 01/08/2013